Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Simulations Plus, Inc. for possible violations of federal securities laws and unlawful business practices [1][3]. Financial Performance - For the third fiscal quarter of 2025, Simulations Plus reported sales of $20.4 million, which was below the consensus estimate of $20.9 million [3]. - The company experienced a net loss of $67.3 million, translating to a diluted loss per share of $3.35, compared to a net income of $3.1 million and diluted earnings per share of $0.15 for the same period in 2024 [3]. - Simulations Plus revised its fiscal 2025 adjusted earnings guidance to a range of $0.93 to $1.06, down from the previous guidance of $1.07 to $1.20 [3]. Stock Market Reaction - Following the financial results announcement, Simulations Plus's stock price fell by $4.50 per share, or 25.76%, closing at $12.97 per share on July 15, 2025 [4]. Company Actions - In June 2025, Simulations Plus initiated a restructuring of its operations, which included workforce reductions and cost-cutting measures aimed at improving operational efficiency and reducing expenses [3].

Financial Data and Key Metrics Changes - The biosimulation market has historically grown at a 15% CAGR but has fallen below that over the last couple of years, with the company achieving 10% organic growth during this period [15][18] - The company's revenue guidance was adjusted due to project cancellations and delays, impacting the expected growth trajectory [16][18] Business Line Data and Key Metrics Changes - The business is composed of approximately 60% software licensing and 40% consulting services, with the software side remaining relatively unaffected by recent market challenges [17][20] - Renewal rates for software licenses remain consistent at over 90%, with fluctuations primarily due to client bankruptcies and consolidations [20][21] Market Data and Key Metrics Changes - The drug development industry is facing cost constraints and reduced funding, leading to tighter budgets among clients [14][15] - The FDA's recent announcements regarding the reduction of animal testing requirements are seen as a potential tailwind for the biosimulation market, which could enhance growth opportunities [23][24] Company Strategy and Development Direction - The acquisition of Proficiency has expanded the company's total addressable market (TAM) from $4 billion to $8 billion, allowing for increased opportunities in clinical operations [5][6] - The company is focusing on integrating various modeling and simulation techniques to enhance product offerings and cross-selling opportunities [29][30] Management's Comments on Operating Environment and Future Outlook - Management noted that the drug development industry does not respond well to surprises, which has led to a slowdown in project approvals and contract negotiations [16][18] - The company anticipates a return to a more steady flow of project requests in fiscal year 2026, with expectations of regaining a growth rate closer to 15% [18][19] Other Important Information - The company is launching a cloud-based platform, Astra Plus, which is expected to enhance functionality and accessibility for clients [33][34] - The integration of AI technology into the company's products is a key focus for future development [31][34] Q&A Session Summary Question: What are the expectations for renewal rates and future fiscal year performance? - Renewal rates are expected to remain stable at over 90%, with the service side impacted by client cancellations but the software side performing well [20][21] Question: How is the FDA's movement away from animal models affecting the company? - The FDA's announcements regarding biosimulation and animal testing are seen as positive developments that could lead to increased adoption of the company's tools [23][24] Question: What is the company's growth formula regarding new and existing clients? - Software revenue typically comes from 80% renewals, 10% upsells, and 10% new clients, with a focus on cross-selling opportunities [29][30]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings and subsequent financial reporting problems [1][2][3]. Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to double its total addressable market and significantly contribute to sales [2][3]. Financial Reporting Issues - The company claimed effective internal controls over financial reporting; however, it appears that there were struggles with the integration of Pro-ficiency and deficiencies in internal controls [3]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025, Simulations Plus's stock fell by $6.39 per share, a decline of over 24%, from $26.44 to $20.05 [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing its auditor Grant Thornton, the stock further declined by $4.50 per share, nearly 26%, from $17.47 to $12.97 [5]. Auditor Dismissal - The dismissal of Grant Thornton was linked to unresolved issues regarding segment reporting and internal controls, which the auditor communicated to management and the Audit Committee [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed successful integration of Pro-ficiency and effective internal controls over financial reporting, which appears to be misleading as the company struggled with integration and lacked effective controls [3] - On April 15, 2025, the company appointed Grant Thornton LLP as its new auditor, but shortly after, on June 11, 2025, it announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties [4] - Following the announcement, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4] - On July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] - The stock price fell again by $4.50, nearly 26%, from $17.47 to $12.97 per share after the impairment charge and auditor dismissal [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed effective internal controls over financial reporting, but evidence suggests struggles with the integration of Pro-ficiency and ineffective internal controls [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings, Inc. and subsequent financial reporting problems [1][2][3]. Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to enhance its market reach and sales [2]. Group 2: Financial Reporting Issues - Simulations Plus claimed that the integration of Pro-ficiency would double its total addressable market and significantly contribute to sales, but it appears the integration was unsuccessful and internal controls were ineffective [3]. - On April 15, 2025, the company appointed Grant Thornton LLP as its new auditor, which later raised concerns about the company's financial reporting [4][5]. Group 3: Stock Performance and Market Reaction - Following the announcement of disappointing preliminary financial results for Q3 2025 on June 11, 2025, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing Grant Thornton, the stock further declined by $4.50, nearly 26%, from $17.47 to $12.97 per share [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Group 2: Financial Performance and Issues - Simulations Plus reported challenges in integrating Pro-ficiency and acknowledged ineffective internal controls over financial reporting [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4] - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results and dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Group 3: Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Group 1 - The Schall Law Firm is investigating claims on behalf of investors of Simulations Plus, Inc. for potential violations of securities laws [1] - The investigation centers on whether Simulations Plus issued false or misleading statements and failed to disclose relevant information to investors [2] - Following the Q3 2025 earnings report, Simulations Plus reported sales of $20.4 million, which was below the consensus estimate of $20.9 million, leading to a decline in the company's shares [2] Group 2 - The preliminary third-quarter sales figures released in June indicated lower expectations at $19 million to $20 million, compared to a consensus of $22.78 million [2]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings, Inc. and subsequent financial reporting problems [1][2][3]. Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to enhance its market reach and sales [2][3]. Group 2: Financial Reporting Issues - The company claimed that the integration of Pro-ficiency would double its total addressable market and significantly contribute to sales, but it appears that the integration was not successful and internal controls were ineffective [3]. - On April 15, 2025, Simulations Plus appointed Grant Thornton LLP as its new auditor, but shortly after, it reported disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties [4]. Group 3: Stock Performance - Following the announcement of disappointing financial results on June 11, 2025, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - On July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed Grant Thornton, which raised concerns about its internal controls and financial reporting [5]. - The stock price fell again by $4.50, nearly 26%, from $17.47 to $12.97 per share after the news of the impairment charge and auditor dismissal [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Group 2: Financial Performance and Issues - Simulations Plus reported disappointing preliminary financial results for Q3 2025, citing market uncertainties as significant headwinds, leading to a stock price drop of over 24% [4] - The company announced a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results, which contributed to a further decline in stock price of nearly 26% [5] - The dismissal of Grant Thornton LLP as the company's auditor raised concerns about internal controls and segment reporting, with the auditor identifying unresolved issues [5]